Journal of Economics and Financial Analysis, 1 (1), pp. 35-58, [2017]
URI: https://ojs.tripaledu.com/index.php/jefa/article/view/8/5

Launch Decisions of Pharmaceutical Companies




DOI: http://dx.doi.org/10.1991/jefa.v1i1.a3

Abstract

This paper models the launch decision of pharmaceutical companies in regard to new drugs and country markets. New drugs are launched with a delay or not launched at all in many countries. Considering that many of these new drugs would have created health benefits to the patients, there seems to be welfare loss. We use market characteristics to explain this phenomenon. We show that most of the estimated launch with a delay and no-launch decision is due to observable market characteristics. The model has an accuracy of 70 percent in explaining the no-launch decision. Intellectual property rights protection is especially important. The policy implication is that stronger property rights increase the likelihood and speed of new drug launch.

Keywords

Drug Launches; Intellectual Property Rights; Pharmaceutical R&D.

JEL Classification

I12, I18.

Full Text:


References

Acemoglu, D., and Linn, J. (2004). Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry. Quarterly Journal of Economics, 119 (August), 1049-1090.

Becker, G. S., Philipson, T. J. & Soares, R. R. (2005). The quantity and quality of life and the evolution of world inequality. American Economic Review, 95 (1), 277–291.

Civan, A., and Maloney, M. (2006). The determinants of pharmaceutical research & development investments. Contributions to Economic Analysis & Policy, 5 (1), 1-36.

Civan, A., and Maloney, M. (2009). The effect of price on pharmaceutical R&D. Contributions to Economic Analysis & Policy, 9 (1), 1-24.

Civan, A., and Koksal, B. (2010). The effect of newer drugs on health spending: Do they really increase the costs? Health Economics, 19 (5), 581–595.

Danzon, P., Wang, R., and Wang, L. (2005). The impact of price regulation on the launch delay of new drugs: evidence from 25 major markets in the1990s. Health Economics, 14 (3), 269–292.

Danzon, P., and Epstein, A. (2008). Effects of regulation on drug launch and pricing in interdependent markets. NBER Working Paper 14041.

Danzon, P., and Furukawa, M. (2008). International Prices and Availability Of Pharmaceuticals In 2005. Health Affairs, 27 (1), 221-233.

Demsetz, H. (1970). The Private Production of Public Goods. Journal of Law and Economics, 8 (2), 293-306.

Djankov, S., La Porta, R., Lopez-de-Silanes, F., and Shleifer, A. (2002). The Regulation of Entry. Quarterly Journal of Economics, 117 (1), 1–38.

Garattini, L., and Ghislandi, S. (2007). Should we really worry about "launch delays" of new drugs in OECD countries? The European Journal of Health Economics, 8 (1), 1-3.

Giaccotto, C., Santerre, R., & Vernon, J.A. (2005). Pricing and R&D Investment Behavior in the Pharmaceutical Industry. Journal of Law and Economics, 48 (1), 195-214.

Heuer, A., Mejer, M., & Neuhaus, J. (2007). The national regulation of pharmaceutical markets and the timing of newdrug launches in Europe. Kiel Advanced Studies Working paper 437. Kiel, Germany: Kiel Institute for the World Economy.

Kanavos, P., Ferrario, A., Vandoros, S., and Anderson, G. (2013). Higher US Branded Drug Prices And Spending Compared To Other Countries May Stem Partly From Quick Uptake Of New Drugs. Health Affairs, 32 (4), 753-761.

Kyle, M. (2007). Pharmaceutical price controls and entry strategies. Review of Economics and Statistics, 89 (1), 88-99.

Lanjouw, J.O. (2005). Patents, price controls and access to new drugs: How policy affects global market entry. NBER working paper No.11321.

Lichtenberg, F. (2001). Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS. Health Affairs, 20 (5), 241-51.

Lichtenberg, F. (2005). The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease-Level Data from 52 Countries, 1982-2001. International Journal of Health Care Finance and Economics, 5 (1), 47-73.

Lichtenberg, F. (2006). The impact of increased utilization of HIV drugs on longevity and medical expenditure: An assessment based on aggregate U.S. time-series data. Expert Review of Pharmacoeconomics and Outcomes Research, 6 (4), 425-436.

Liu, M., and La Croix, S. (2008). A cross-country index of intellectual property rights in pharmaceutical Innovations. Unpublished manuscript

Murphy, K., and Topel, R. (2003). The economic value of medical research. In K. Murphy & R. Topel (Eds.), Measuring the Gains from Medical Research: An Economic Approach. The University of Chicago Press.

Oster, E., Shoulson, I., and Dorsey, R. (2012). Limited Life Expectancy, Human Capital and Health Investments: Evidence from Huntington Disease. NBER Working Paper No. 17931

Rosen, S. (1988). The value of changes in life expectancy. Journal of Risk and Uncertainty, 1(3), 285-304.

Soares, R.R. (2007). Health and the evolution of welfare across Brazilian municipalities. Journal of Development Economics, 84 (2), 590-608.




Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.